CN101669934B - application of mango aglycone in preparing medicine for obesity - Google Patents
application of mango aglycone in preparing medicine for obesity Download PDFInfo
- Publication number
- CN101669934B CN101669934B CN200910184185.5A CN200910184185A CN101669934B CN 101669934 B CN101669934 B CN 101669934B CN 200910184185 A CN200910184185 A CN 200910184185A CN 101669934 B CN101669934 B CN 101669934B
- Authority
- CN
- China
- Prior art keywords
- ptp1b
- mango aglycone
- insulin
- mango
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000004936 Bromus mango Nutrition 0.000 title claims abstract description 29
- 235000014826 Mangifera indica Nutrition 0.000 title claims abstract description 29
- 235000009184 Spondias indica Nutrition 0.000 title claims abstract description 29
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 title claims abstract description 26
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 title claims abstract description 26
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 208000008589 Obesity Diseases 0.000 title claims abstract description 6
- 235000020824 obesity Nutrition 0.000 title claims abstract description 6
- 240000007228 Mangifera indica Species 0.000 title claims 2
- 241001093152 Mangifera Species 0.000 abstract description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 24
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 102000004877 Insulin Human genes 0.000 abstract description 12
- 108090001061 Insulin Proteins 0.000 abstract description 12
- 229940125396 insulin Drugs 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 8
- 230000001629 suppression Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- ZHTQCPCDXKMMLU-UHFFFAOYSA-N norathyriol Chemical compound OC1=C(O)C=C2C(=O)C3=C(O)C=C(O)C=C3OC2=C1 ZHTQCPCDXKMMLU-UHFFFAOYSA-N 0.000 abstract description 6
- 238000011740 C57BL/6 mouse Methods 0.000 abstract description 5
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract description 5
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 230000002860 competitive effect Effects 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 150000002611 lead compounds Chemical class 0.000 abstract description 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 4
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 6
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 3
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- SXKBTDJJEQQEGE-UHFFFAOYSA-N 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide Chemical compound CCC=1OC2=CC(S(=O)(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3SC=CN=3)=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SXKBTDJJEQQEGE-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000049286 human PTPN1 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of biological pharmacy, and in particular relates to suppressive activity detection of tetrahydroxy norathyriol on protein-tyrosine-phosphatase (PTP) 1B, improvement of resistance function of insulin and accpication in medicament for PTP1B related diseases. Proved by in vitro enzyme suppression experiments, the invention testifies that mango aglycone is the competitive suppressant of restructuring humanized PTP1B with IC50 value being 9.2 mu m; mango aglycone can ensure the sensitivity of C57BL/6 normal mouse and ob/ob diabetes model mouse on insulin to be obviously improved, and reduce blood sugar of experimental animals, which suggests that mango aglycone is a novel suppressant of PTP1B, and can be taken as potential lead compound to be applied in preparing medicament for curing insulin resistance related diabetes, obesity and other metabolic syndrome, tumor and other PTP1B related diseases.
Description
Technical field
The invention belongs to biological pharmacy technical field, be specifically related to mango aglycone active to the inhibition of PTP 1B (PTP1B), improve Insulin Resistance, and in the preparation treatment
Application in the medicine of metabolism syndrome, tumor and other PTP1B relevant diseases such as type diabetes, obesity.
Background technology
The phosphorylation level of protein-tyrosine is the important adjusting factor of intracellular signal transduction, it is by protein tyrosine kinase (Proteintyrosine kinase, PTK) and Protein-tyrosine-phosphatase (Protein tyrosine phosphatase, PTP) common regulation and control, PTP1B (Protein tyrosine phosphatase 1B, PTP1B) belong to PTP family, be negative regulatory factor important in the insulin signaling pathway and participate in leptin, multiple somatomedin, prolactin antagonist, integrin, the signal transduction process of platelet agglutinin etc., with diabetes, fat insulin resistant and leptin resistance all have substantial connection, with insulin resistant, fat, 4 metabolism syndrome Major Risk Factors such as metabolism disorder of blood lipid and hypertension significant correlation is in the generation of metabolism syndrome, play an important role in the development.PTP1B knock out mice insulin sensitivity significantly improves, and can keep good sugared stable state.In addition, the transfer that PTP1B can also inhibition tumor cell with apoptosis of tumor cells, associated angiogenesis, plays the negative regulation effect in the signal transduction of prolactin antagonist-prolactin antagonist in mammary gland and epithelial cell.PTP1B has become novel, the important drug targets of various diseases such as treatment type ii diabetes, obesity, breast carcinoma, plays an important role in the diseases such as control metabolism syndrome, tumor, and the research of its inhibitor has also been become present study hotspot.
Mango aglycone (norathyriol, NL), full name 1,3,6,7-tetrahydroxy
Ketone (1,3,6,7-tetrahydroxyxanthone), its chemical structural formula is as follows:
Modern pharmacological research shows that mango aglycone has multiple physiological action, and such as effects such as antidepressant, antiinflammatory, resisting hypertension, antitumor, antioxidation and inhibition growth of bacillus tubercle, wherein the research of antiinflammatory action is comparatively deep.But have not yet to see the research report that it suppresses PTP1B, improves the insulin sensitivity aspect.
Summary of the invention
It is active to the inhibition of PTP 1B to the objective of the invention is to be devoted to study mango aglycone, for people provide a kind of new protein-tyrosine phosphatase 1B inhibitor, and by the inhibition activity of research mango aglycone to PTP 1B, further expand the medicinal usage of mango aglycone.
For achieving the above object, the applicant is studied from the following aspects:
1, set up Protein-tyrosine-phosphatase and suppress the active reaction system that detects, producing color reaction according to the phosphate group of PTP1B hydrolysis pNPP, to detect chemical micromolecule active to the inhibition of PTP1B, and be used for measuring mango aglycone and suppress activity and comprise IC
50Value and inhibitor type.
By above-mentioned in vitro tests, the applicant finds that mango aglycone can significantly suppress the PTP1B activity, is a kind of novel PTP1B inhibitor, and it suppresses type is competitive inhibition;
2, by the in vivo test of mice, the applicant finds that mango aglycone can significantly improve the insulin sensitivity of C57BL/6 normal mouse and the ob/ob diabetes obese model mice take insulin resistant as feature, reduces laboratory animal blood glucose.
Based on above-mentioned research and test, the applicant has confirmed that first mango aglycone is preferably novel PTP1B competitive inhibitor of activity, can increase insulin sensitivity in vivo, improve the hyperglycemia symptom of laboratory animal, can be for the preparation of improving insulin sensitivity, hypoglycemic medicine, can become potential treatment type ii diabetes, the fat metabolism syndrome that waits, the thing of breast carcinoma medicine, and can be used as potential lead compound and carry out anti-diabetic, the fat metabolism syndrome that waits, tumor and other are developed with the medicine of PTP1B relevant disease, and can be by the further research metabolism signal path of being correlated with such as chip technology.
Description of drawings
Fig. 1: sodium vanadate is to PTP1B suppression ratio curve chart partially.
Measure the inclined to one side sodium vanadate (NaVO of positive control of variable concentrations
3) to recombined human source protein tyrosine phosphatase 1B suppression ratio, the relative concentration mapping obtains NaVO
3IC
50Be 0.32 μ M.
Fig. 2: mango aglycone is to PTP1B suppression ratio curve chart.
Measure the variable concentrations mango aglycone to recombined human source protein tyrosine phosphatase 1B suppression ratio curve, relative concentration mapping, its IC
50Be 9.2 μ M.
Fig. 3: the double reciprocal plot that mango aglycone suppresses PTP1B.
Under the condition that enzyme exists, the fixing concentration of inhibitor, change the concentration of substrate, use the Lineweaver-Burk method, take 1/s as abscissa, 1/V obtains five regression straight lines as vertical coordinate mapping, these five straight lines meet at Y-axis, thereby judge that mango aglycone is competitive inhibition to the inhibition type of PTP1B.
Fig. 4: mango aglycone is to normal ip in mice. the change of blood sugar figure of insulin.
Data are carried out statistical procedures (n=11) with the ANOVA method, wherein respectively organize blood sugar level and compare with matched group, NL (5,40mg/kg) 30,60,90, four time points of 120min have significant difference * p＜0.05.
Fig. 5: mango aglycone is to the ob/ob ip in mice. the change of blood sugar figure of insulin.
Data are carried out statistical procedures (n=5) with the ANOVA method, wherein respectively organize blood sugar level and compare with matched group, NL (40mg/kg) 60,90, three time points of 120min have significant difference * p＜0.05.
The specific embodiment
Further describe the present invention by following examples, but should notice that scope of the present invention is not subjected to any restriction of these embodiment.
Material and source:
Reagent: mango aglycone; Recombination human source PTP1B (Merck); 4-NPP pNPP (Sigma); Inclined to one side sodium vanadate (Sigma); MOPS (Sigma); DTT (Sigma); Insulin (Jiangsu Wanbang Biological Pharmaceutical Co., Ltd.); C57BL/6 mice (Military Medical Science Institute's Experimental Animal Center), ob/ob mice (Jackson Lab).
Equipment: XFLOUR4 microplate reader; Constant incubator; The steady bold and unconstrained blood glucose meter of Johnson ﹠ Johnson
Mango aglycone is rear with the dilution of MOPS buffer with a small amount of DMSO dissolving, get 10 μ l and be added to that (pH 7.0 in the 100 μ l reaction systems, 25mM mops, 1mM EDTA, 2mM DTT, 0.1M NaCl), make its final concentration be respectively 1500,150,15,1.5,0.15 μ M, add substrate pNPP to 16mM, add recombined human PTP1B 5ng and be placed on 37 ℃ of reaction 30min.Add 10 μ l1M NaOH cessation reactions, put the absorption value A that measures on the microplate reader under the 405nm wavelength condition, with inclined to one side sodium vanadate (NaVO
3) as positive control, not add PTP1B as blank, calculate suppression ratio.With suppression ratio concentration is figure, obtains mango aglycone IC
50Be 9.2 μ M, inclined to one side sodium vanadate IC
50Be 0.32 μ M.
Prepare respectively the pNPP (32,16,8,4,2mM) of variable concentrations and the NL solution (1.25,2.5,5,10,20 μ M) of variable concentrations.The corresponding 5 groups of pNPP concentration of each NL concentration are done the inhibition determination of activity, obtain V according to the variation of OD405, and corresponding concentration of substrate is S, maps respectively according to the L-B equation.The result shows that each bar straight line meets at Y-axis, is the state of conflict inhibitor of PTP1B so can judge NL.
The C57BL/6 mice is divided into 5 groups at random, 11 every group, is respectively matched group, NL various dose administration group (100,60,40,15mg/kg).Administration group respectively gavage gives the NL (with 0.5%CMC-Na aqueous solution suspendible) of variable concentrations, and the matched group gavage gives the 0.5%CMC-Na aqueous solution.Successive administration 7 days, fasting 12h after the last administration presses 1U/kg lumbar injection insulin, respectively at 0,15,30,60,90,120min gets blood measuring blood value.
Insulin tolerance experiment (Insulin Tolerance Test, ITT) experiment shows, NL (5,40mg/kg) can significantly improve C57BL/6 mouse islets element sensitivity, reduces its blood glucose, at rear four time points significant difference (p＜0.05) is arranged.
The ob/ob mice is divided into 2 groups at random, and 5 every group, be respectively matched group and administration group, administration group gavage gives 40mg/kg NL solution (with 0.5%CMC-Na aqueous solution suspendible), and the matched group gavage gives the 0.5%CMC-Na aqueous solution.Continuously gavage is 7 days, and fasting 12h after the last administration presses 1U/kg lumbar injection insulin, respectively 0,15,30,60,90,120min gets blood measuring blood value.
ITT tests demonstration, and 40mg/kg dosage NL can significantly improve ob/ob mouse islets element sensitivity, reduces its hyperglycemia symptom, at rear three time points significant difference (p＜0.05) is arranged.
Claims (1)
1. the application of mango aglycone in the medicine of preparation treatment of obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910184185.5A CN101669934B (en) | 2009-08-21 | 2009-08-21 | application of mango aglycone in preparing medicine for obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910184185.5A CN101669934B (en) | 2009-08-21 | 2009-08-21 | application of mango aglycone in preparing medicine for obesity |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101040859A Division CN102657640A (en) | 2009-08-21 | 2009-08-21 | PTP1B (protein tyrosine phosphatase 1B) inhibition activity of norathyriol, and application of norathyriol |
| CN2012101019063A Division CN102670582A (en) | 2009-08-21 | 2009-08-21 | Inhibitory activity of norathyriol to protein tyrosine phosphatase 1B (PTP1B) and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101669934A CN101669934A (en) | 2010-03-17 |
| CN101669934B true CN101669934B (en) | 2013-05-29 |
Family
ID=42017493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910184185.5A Expired - Fee Related CN101669934B (en) | 2009-08-21 | 2009-08-21 | application of mango aglycone in preparing medicine for obesity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101669934B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102590367A (en) * | 2011-01-07 | 2012-07-18 | 昆明制药集团股份有限公司 | Method for detecting mangiferin aglycon |
| CN102807548B (en) * | 2011-05-30 | 2014-10-22 | 昆明制药集团股份有限公司 | Norathyriol crystal I and preparation method thereof |
| CN102920696B (en) * | 2012-09-27 | 2015-03-18 | 戴好富 | Application of mangiferin compound or mango extraction as pancreatic lipase inhibitor and in preparation of medicament or food for preventing and treating obesity |
| CN104288139B (en) * | 2014-09-17 | 2016-05-18 | 昆药集团股份有限公司 | Mango aglycone derivative is prevented and treated the application in diabetes and complication medicine thereof in preparation |
| CN107362159A (en) * | 2016-05-13 | 2017-11-21 | 上海交通大学医学院 | The application of Xanthones ketone compounds and its derivative in blood lipid-lowering medicine is prepared |
| CN112479849A (en) * | 2020-12-15 | 2021-03-12 | 北京工商大学 | Compound and application thereof |
| CN114288296B (en) * | 2022-01-27 | 2022-11-29 | 浙江省中医药研究院 | Pharmaceutical composition and application thereof in preparing anti-osteoporosis medicine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284001A (en) * | 2008-01-23 | 2008-10-15 | 南京大学 | Application of mangiferin in treating type II diabetes and vitro trial model thereof |
| CN101367787A (en) * | 2008-10-13 | 2009-02-18 | 南京大学 | Mango aglycone, preparation purification process and uses thereof |
-
2009
- 2009-08-21 CN CN200910184185.5A patent/CN101669934B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284001A (en) * | 2008-01-23 | 2008-10-15 | 南京大学 | Application of mangiferin in treating type II diabetes and vitro trial model thereof |
| CN101367787A (en) * | 2008-10-13 | 2009-02-18 | 南京大学 | Mango aglycone, preparation purification process and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101669934A (en) | 2010-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101669934B (en) | application of mango aglycone in preparing medicine for obesity | |
| CN102725263A (en) | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | |
| WO2011032169A2 (en) | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same | |
| CN101450934A (en) | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | |
| Shi et al. | In vitro and in vivo effects of norathyriol and mangiferin on α-glucosidase | |
| US11033550B2 (en) | Medicament | |
| CN102086172A (en) | Medicinal salts of saxagliptin and preparation methods of medicinal salts | |
| Chen et al. | Binding interaction of betulinic acid to α-glucosidase and its alleviation on postprandial hyperglycemia | |
| CN103919778A (en) | Application of curcumin analog S1 containing piperidone structure in preparation of anti-inflammation drugs | |
| Berabez et al. | LIM kinases, promising but reluctant therapeutic targets: chemistry and preclinical validation in vivo | |
| CN106278907B (en) | A kind of Syprine Hydrochloride compound | |
| CN102670582A (en) | Inhibitory activity of norathyriol to protein tyrosine phosphatase 1B (PTP1B) and application thereof | |
| CN102657640A (en) | PTP1B (protein tyrosine phosphatase 1B) inhibition activity of norathyriol, and application of norathyriol | |
| CN105982895A (en) | TOPK inhibitor as antitumor drug | |
| CN105566329B (en) | A kind of pyrazoles [5,6-d] miazines EGFR inhibitor and its anti-tumor activity | |
| CN104983729A (en) | New application of catechin compound and gallic acid combination to preparation of hyperuricemia treatment medicine | |
| CN103936742A (en) | Novel PI3K inhibitor containing purine radicals, preparation method and applications thereof | |
| CN104211747A (en) | Preparation and medical applications of 5'-phosphoric acid-N6-(3-hydroxylphenyl)adenosine | |
| CN104725372B (en) | Tetracyclic indole alkaloid derivative as well as preparation method and application thereof | |
| Sip et al. | Amorphous Form of Carvedilol Phosphate—The Case of Divergent Properties | |
| CN105030755A (en) | Novel application of catechin compounds in preparation of medicaments for treating hyperuricemia | |
| CN105777739B (en) | Naphthylamino thiazole methyl qualone derivative and its medical usage | |
| CN109908156A (en) | Tanshinone IIA is inhibiting the application in the aggregation of Tau abnormal protein | |
| CN103467452A (en) | Benzamide compounds and application thereof | |
| CN103304504B (en) | Anti-diabetic compound, as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130529 Termination date: 20160821 |